Trio goes in for high tech medicines
The Swedish drug discovery company Beactica announces fragment-based drug discovery research collaboration with GE Healthcare and the University of Uppsala.
This newly announced collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from the University of Uppsala.
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore surface plasmon resonance instruments and applications for fragmentbased drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica’s discovery pipeline.